Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use
AssigneeUniversity of South Florida
InventorsThomas W. Klein, Tracy Sherwood, Liang Nong, Cathy Newton
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of South Florida
InventorsThomas W. Klein, Tracy Sherwood, Liang Nong, Cathy Newton
Estimating the term…
Cannabinoid receptor 2 (CB2) is expressed in B lymphocytes and is involved in immune regulation. Mouse splenic B cells express three CB2 transcripts utilizing two different first exons. Human peripheral blood B cells express one CB2 transcript utilizing one first exon. Alignment of sequenced RACE products to either the mouse or human genome reveals that isolated transcripts contain previously unidentified transcriptional start sites (TSS). B cells from mouse and human preferentially express one transcript, exon 1a in mouse and exon 1 in human. Multiple CB2 TSSs are utilized in mouse splenic B cells and one TSS in human peripheral blood B cells. The defining of the receptor gene TSSs in these cells provides materials and methods for therapeutically regulating immune function, including antibody isotype switching, using compounds such as inhibitory nucleic acids that down-regulate expression of the B cell CB2 gene (e.g., RNAi molecules).
A method of reducing the expression of a B cell CB2 receptor gene, comprising contacting the B cell with one or more inhibitory nucleic acid molecules comprising a nucleic acid sequence that targets a sequence (nucleic acid target sequence within or overlapping with the transcription start site associated with the B cell CB2 receptor gene promoter region within the cell, thereby reducing expression of the B cell CB2 receptor gene.
Dependencies are inferred from the claim text.